What is the process in which clots dissolve in the body during the healing phase of clotting?

Choice A rationale

Chronic renal failure typically leads to a decreased hemoglobin level, not an increase. The kidneys are responsible for producing erythropoietin, a hormone that stimulates the bone marrow to produce red blood cells. As renal function declines, erythropoietin production drops, leading to anemia of chronic disease. Normal hemoglobin for men is 13.5 to 17.5 g/dL and for women is 12.0 to 15.5 g/dL. Patients with kidney failure usually show levels significantly below these standard reference ranges.

Choice B rationale

A decreased glomerular filtration rate is the hallmark of chronic renal failure, not an increased rate. The filtration rate measures how well the kidneys clear waste from the blood. A normal rate is generally above 90 mL/min/1.73m. As the nephrons are damaged and lost over time, the kidneys' ability to filter blood diminishes, leading to the accumulation of toxins. An increasing rate would signify improving kidney function, which is the opposite of the progressive decline seen in failure.

Choice C rationale

An increased serum potassium level, or hyperkalemia, is a classic finding in chronic renal failure. The kidneys are the primary route for potassium excretion from the body. When they fail, potassium builds up in the blood. Normal serum potassium is 3.5 to 5.0 mEq/L. Levels above this range are dangerous as they can lead to life-threatening cardiac arrhythmias. Managing dietary intake and using medications to lower potassium are critical interventions for patients with advanced stages of kidney disease.

Choice D rationale

Chronic renal failure usually results in a decreased serum calcium level, also known as hypocalcemia. This happens because the kidneys cannot activate vitamin D, which is necessary for calcium absorption in the gut. Furthermore, phosphate levels rise because the kidneys cannot excrete it, and high phosphate levels further drive down calcium. Normal serum calcium is 8.5 to 10.5 mg/dL. The resulting imbalance often leads to secondary hyperparathyroidism and bone disease as the body tries to compensate.

Choice A rationale

Alzheimer's disease is pathologically defined by the extracellular accumulation of beta-amyloid plaques and the intracellular formation of neurofibrillary tangles composed of hyperphosphorylated tau protein. These abnormal protein aggregates disrupt neuronal communication and lead to cell death, beginning in the hippocampus and spreading through the cerebral cortex. This specific proteinopathy is the gold standard for diagnosing Alzheimer's and distinguishes it from other forms of cognitive decline that have different underlying cellular mechanisms and protein involvements.

Choice B rationale

Vascular dementia is caused by impaired blood flow to the brain, often resulting from a series of small strokes, chronic hypertension, or large-vessel disease. The primary pathology involves ischemic damage, infarctions, and white matter changes rather than the primary accumulation of amyloid and tau. While a person can have mixed dementia involving both vascular and Alzheimer's changes, the defining characteristic of pure vascular dementia is the loss of brain tissue due to lack of oxygen and nutrients.

Choice C rationale

Frontotemporal dementia is a group of disorders characterized by the degeneration of the frontal and temporal lobes. While it does involve abnormal proteins, such as TDP-43 or tau, it does not typically feature the beta-amyloid plaques that are characteristic of Alzheimer's disease. The clinical presentation also differs, usually focusing more on early changes in personality, social behavior, and language rather than the memory loss and specific amyloid-tau dual pathology found in the early stages of Alzheimer's disease.

Choice D rationale

Lewy body dementia is characterized by the accumulation of alpha-synuclein protein deposits, known as Lewy bodies, in the brain. While patients with Lewy body dementia may also have some amyloid plaques, the primary driving force behind the cognitive decline, visual hallucinations, and motor symptoms is the synucleinopathy. This distinguishes it from Alzheimer's disease, where the focus is on amyloid and tau, although there is sometimes overlap in the pathological findings of older patients with multiple conditions.